Compliance Dashboard

FDA, FTC, PCAC, and 503A compliance posture across the platform.

High Priority

CMP-01

NA Bioscience FDA 510 Registration Verification

Compliance attorney must verify API manufacturer registration before routing into 503A channel.

Due
Jul 01, 2026

Action Required

CMP-02

Adverse Event Reporting SOP

Drafting SOP for clinic-reported AEs across all peptide products.

Due
Jul 10, 2026

In Progress

CMP-03

Marketing Claim Review — All Materials

FDA/FTC review of every clinic-facing marketing asset before distribution.

Due
Jul 15, 2026

In Progress

CMP-04

PCAC Meeting Monitoring

BPC-157, TB-500, MOTS-C, Semax, KPV — live monitor day-of.

Due
Jul 23–24, 2026

Scheduled

Standard

CMP-05

State Pharmacy Licensure Audit

Confirm 50-state coverage of Empower; gap-fill via Massey/NDL.

Due
Aug 01, 2026

In Progress

CMP-06

Patient-Specific Rx Verification Workflow

Implemented across all active clinics.

Due
May 30, 2026

Complete

CMP-07

503A vs 503B Channel Documentation

Routing rules documented for each product.

Due
Jun 01, 2026

Complete

CMP-08

HIPAA Business Associate Agreements

BAAs with each pharmacy partner.

Due
Jul 30, 2026

In Progress

CMP-09

GHK-Cu Non-Injectable Category 1 Filing

Filed post-FDA restoration.

Due
May 14, 2026

Complete

CMP-10

Annual Compliance Training — All Staff

Schedule Q3 training.

Due
Sep 01, 2026

Pending